2001
Effect of Non–Insulin-Dependent Diabetes Mellitus on Myocardial Insulin Responsiveness in Patients With Ischemic Heart Disease
Jagasia D, Whiting J, Concato J, Pfau S, McNulty P. Effect of Non–Insulin-Dependent Diabetes Mellitus on Myocardial Insulin Responsiveness in Patients With Ischemic Heart Disease. Circulation 2001, 103: 1734-1739. PMID: 11282903, DOI: 10.1161/01.cir.103.13.1734.Peer-Reviewed Original ResearchConceptsGlucose uptakeMyocardial insulin responsivenessCoronary disease patientsCoronary blood flowDependent diabetes mellitusIschemic heart diseaseMyocardium of patientsPoor clinical outcomeNet lactate uptakeCardiac glucose uptakeFractional extractionClinical outcomesDiabetes mellitusNon-InsulinInsulin levelsInsulin resistanceCardiac responsivenessDisease patientsInsulin infusionHeart diseaseMyocardial ischemiaPeripheral tissuesGlucose levelsBlood flowArterial plasma
2000
Effect of plasma insulin level on myocardial blood flow and its mechanism of action
McNulty P, Pfau S, Deckelbaum L. Effect of plasma insulin level on myocardial blood flow and its mechanism of action. The American Journal Of Cardiology 2000, 85: 161-165. PMID: 10955370, DOI: 10.1016/s0002-9149(99)00650-5.Peer-Reviewed Original ResearchConceptsMyocardial blood flowBlood flowInsulin levelsInsulin concentrationsCoronary sinus blood flowSystemic insulin levelsVenous plasma insulinSinus blood flowMyocardial oxygen demandCoronary blood flowCoronary heart diseasePlasma insulin levelsPlasma insulin concentrationMyocardial oxygen consumptionOxidative substrate metabolismMechanism of actionCoronary toneVasoactive substancesIntracoronary infusionCoronary endotheliumCoronary circulationPlasma insulinInsulin infusionHeart diseasePhysiologic elevations
1993
Initiation of cardiac allograft rejection New developments in cellular and molecular mechanisms
Pfau S, Bender J. Initiation of cardiac allograft rejection New developments in cellular and molecular mechanisms. Trends In Cardiovascular Medicine 1993, 3: 196-203. PMID: 21244933, DOI: 10.1016/1050-1738(93)90006-r.Peer-Reviewed Original ResearchT cell activationEnd-stage heart diseaseEffective immunosuppressive therapyNatural killer lymphocytesImmune effector cellsViable therapeutic optionT lymphocyte recognitionT cell biologyEarly eventsCardiac transplantationImmunosuppressive therapyMedical complicationsEffector cellsTherapeutic optionsCytokine productionInflammatory cellsHeart diseaseKiller lymphocytesForeign antigensT cellsImmune responseClinical utilityVascular endotheliumRejection processLong-term success